BrightGene Bio-medical Technology(SH:688166) Xin Lang Cai Jing·2025-06-27 08:22Group 1 - The company, Borui Biopharmaceutical (Suzhou) Co., Ltd., approved a proposal to use up to RMB 380 million of temporarily idle raised funds for cash management, with a usage period not exceeding 12 months from the date of board approval [1] - The company failed to redeem the cash management products in a timely manner by the deadline of November 26, 2020, and did not hold a board meeting to review the cash management situation until December 11, 2020, violating disclosure obligations [1] - The actions of the company were found to be in violation of the relevant regulations regarding information disclosure and management of raised funds [1] Group 2 - The financial director, Zou Yuanlai, did not fulfill his responsibilities in ensuring the proper use of raised funds and timely disclosure of related information, which also constituted a violation of regulations [2] - The Jiangsu Securities Regulatory Bureau decided to issue a warning letter as an administrative regulatory measure and record it in the securities and futures market integrity file [2] - The company is required to enhance compliance awareness and submit a written report to the regulatory bureau within 10 working days of receiving the decision [2]